Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Chugai Won’t Challenge Edirol Substance Patent Ruling
March 11, 2022
-
REGULATORY Panel Confirms Backing for Alexion’s Bleeding Antidote after Data Integrity Issues
March 10, 2022
-
BUSINESS Japan Drug Makers Moving to Support War-Hit Ukraine
March 10, 2022
-
BUSINESS Double-Digit Slashes to Hit 44 Major Drugs in 2022 Price Revision: Top 5 Product Poll
March 9, 2022
-
REGULATORY MHLW Publishes Brand-by-Brand Supply Status for 130 APIs Subject to Its Restriction Lifting Request
March 9, 2022
-
ORGANIZATION Apply Only Market Price-Linked Rules in Next Off-Year Revision, No Hasty Debate for Adjustment Rate: JMA Official
March 8, 2022
-
BUSINESS SanBio’s Sakigake Cell Therapy Finally Filed in Japan for Traumatic Brain Injury
March 8, 2022
-
BUSINESS Eisai Suffers 9%-Plus Cut, Sumitomo Dainippon Over 8% in 2022 Drug Price Revision: Jiho Poll
March 7, 2022
-
REGULATORY Takecab Faces 15.8% Slash, GLP-1s 11.1% in FY2022 Drug Price Revision
March 4, 2022
-
REGULATORY Outgoing Chair of Unapproved Drug Council Boasts 300 Approvals Achieved to Cut Lag, Urges New Reimbursement Scheme
March 4, 2022
-
BUSINESS AZ Japan Working towards 100% Electric Vehicle Fleet by 2025, but Challenges Remain
March 3, 2022
-
REGULATORY Alexion’s Bleeding Antidote Up for PAFSC Discussion Again after Data Integrity Issues
March 3, 2022
-
BUSINESS Zogenix Sees Its Pipeline Drugs Continue to Be Developed in Japan after UCB Deal
March 2, 2022
-
BUSINESS Drugs Might Get Hit by SWIFT Ban on Russia Even If Exempted from Trade Sanctions
March 1, 2022
-
BUSINESS Ono Sues AstraZeneca over PD-L1 Patent, Seeks 32 Billion Yen in Damage
March 1, 2022
-
REGULATORY MHLW Approves Label Expansions for Retevmo, Keytruda, Lenvima and More
February 28, 2022
-
ORGANIZATION Impact of Ukraine Invasion Limited in Japan? Trader Group Says Epirubicin Is Only API Possibly Affected
February 25, 2022
-
BUSINESS Tokyo Court Rejects Chugai’s Claim over Edirol Substance Patent
February 25, 2022
-
BUSINESS Medicago’s COVID-19 Vaccine Approved in Canada
February 25, 2022
-
ORGANIZATION Chuikyo Payer Rep Wants Category-Based Debate on Adjustment Rate, Prods PMP Cuts in Next Off-Year Revision
February 24, 2022
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…